To his role as Chief Financial Officer, Hugh brings a wealth of experience and strategic financial insight, having served for nearly three decades in financial, accounting and business transformation capacities within international manufacturing enterprises. Prior to joining LenioBio, he has held the role of Chief Financial Officer in several businesses, including a private equity-backed food startup and key positions within international publicly-listed companies including Synthomer PLC and Bakkavor Group.
André Goerke, Chief Executive Officer of LenioBio welcomed the newest addition to the leadership team, “I am pleased to welcome Hugh to the team. His industry experience and financial expertise will be essential, as we step into the next phase of commercializing our innovative manufacturing platform.”
Hugh is inspired by the transformative potential of LenioBio’s protein expression technology, “The therapeutic drug development landscape is evolving, and we have the capability to effect positive change in how scientists access and work with proteins. This is truly exciting! I look forward to contributing my skills and experience to the team as we continue our journey from scientific discovery to seizing commercial opportunities.”
About LenioBio:
LenioBio GmbH is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell. LenioBio was established as a legal entity in Germany in September 2016, with offices in Dusseldorf and R&D and production labs in Aachen. For more information about LenioBio, please visit our website at www.leniobio.com and follow LenioBio on LinkedIn.